News Quantified

BCEL – atreca, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - BCEL, CTLT, NS, SCX

Immunome: An Oncology Powerhouse In The Making [Seeking Alpha]

Nested Therapeutics Strengthens Board of Directors with Appointment of New Chair and Directors [Yahoo! Finance]

-23.0%

MISS

-36.6%

BEAT

-14.9%

BEAT

Form DEFM14A Atreca, Inc.

Form 4 Atreca, Inc. For: Apr 11 Filed by: Orwin John A

Form PREM14A Atreca, Inc. For: May 13

Form 4 Atreca, Inc. For: Apr 01 Filed by: Serafini Tito

Form 4 Atreca, Inc. For: Sep 01 Filed by: Orwin John A

Top News Gainers

12/3 Atreca Announces FDA Clearance of Investigational New Drug Application for ATRC-101 32.3%

3/19 Form 4 Atreca, Inc. For: Mar 17 Filed by: Orwin John A 25.4%

3/12 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atreca, Inc. - BCEL 24.6%

12/4 Atreca (NASDAQ: BCEL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. 21.6%

2/7 Form SC 13G Atreca, Inc. Filed by: BlackRock Inc. 9.4%

6/20 Biopharma firm Atreca goes public [Reuters] 8.7%

4/21 Atreca (NASDAQ: BCEL) is now covered by analysts at Wedbush. They set an "outperform" rating on the stock. 6.6%

2/14 Form SC 13G/A Atreca, Inc. Filed by: Redmile Group, LLC 5.1%

6/25 Form SC 13G Atreca, Inc. Filed by: Redmile Group, LLC 4.9%

11/5 Atreca to Highlight ATRC-101 Preclinical Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting 4.7%

Top News Decliners

3/14 Atreca (NASDAQ: BCEL) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -27.6%

3/11 Q4/2019 12/31/2019 EPS -0.720 ZacksConsensus -0.640 ActVsEst (0.080) - Miss -22.7%

4/29 Form DEF 14A Atreca, Inc. For: Jun 10 -15.8%

7/10 Form SC 13G Atreca, Inc. Filed by: WELLINGTON MANAGEMENT GROUP LLP -13.7%

7/1 Form SC 13G Atreca, Inc. Filed by: Boxer Capital, LLC -13.7%

8/14 Atreca (NASDAQ: BCEL) had its "buy" rating re-affirmed by analysts at Cowen Inc. -13.7%

4/15 Atreca (NASDAQ: BCEL) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. -9.3%

6/19 Form 3 Atreca, Inc. For: Jun 19 Filed by: ATWOOD BRIAN G -9.3%

3/4 Form 4 Atreca, Inc. For: Mar 02 Filed by: Greenberg Norman Michael -9.1%

6/20 Form 424B4 Atreca, Inc. -8.8%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day